New York, New York–(Newsfile Corp. – November 18, 2020) – NanoViricides, Inc. (NYSE American: NNVC) (the “Company”) a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, was the subject of a recent article on leading financial news website and publisher, Small Caps Daily. NanoViricides’ progress and advancement to clinical trials, developing a therapy to combat COVID-19 and an exploration of the technology behind NV-CoV-1, which is NanoViricides’ drug candidate, were a few of the topics covered in the Small Caps Daily article. After recently passing the first anniversary of the first case of COVID-19 discovered in the Wuhan province of China, the world waits with bated breath on therapies and vaccines to combat the deadly disease. NanoViricides is currently in the process of filing the Investigational New Drug (IND) application with the U.S. Food and Drugs Authority (FDA) after completing its drug development process using its unique nanomedicine technology called nanoviricides.
Key Takeaways from the SmallCapsDaily article featuring NanoViricides:
- NanoViricides therapy offers a strong possibility of enhancement of the effectiveness of remdesivir-based therapies, is easily the most consumed COVID-19 drug today. The NV-CoV-1-R therapy, a combination of remdesivir and the NV-CoV-1, encapsulates remdesivir as the participating drug for blocking the viral replication cycle in order to protect it from metabolism in the body
- NanoViricides’ technology has shown a lot of promise which is why the company is in a great cash position. In its most recent 10Q filing, management reported that it had approximately $22 million in the form of current assets i.e. cash, cash equivalents, and prepaid expenses
- NanoViricides was recently in the news for engaging renowned CRO (contract research organization), Calvert Labs for the purpose of performing the Safety Pharmacology studies on the NV-CoV-1.
For more insight into NanoViricides, Inc., and to continue reading the Small Caps Daily featured article, please click here: https://smallcapsdaily.com/nanoviricides-rapidly-advancing-towards-clinical-trials/
SmallCapsDaily profiles are not a solicitation or recommendation to buy, sell or hold securities. SmallCapsDaily is a paid advertiser and is not offering securities for sale. Neither SmallCapsDaily nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by SmallCapsDaily its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. Small Caps Daily does not recommend that the securities profiled should be purchased, sold or held and is not liable for any investment decisions by its readers or subscribers. Information presented by Small Caps Daily may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance, are not statements of historical fact and may be “forward-looking statements.” Forward-looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements may be identified through the use of words such as “expects,” “will,” “anticipates,” “estimates,” “believes,” “may,” or by statements indicating that certain actions “may,” “could,” or “might” occur.